By Val Brickates Kennedy
Shares of partners Elan Corp. (ELN) and Wyeth (WYE) both moved lower Thursday after the companies said they were discontinuing part of a Phase III clinical trial for their Alzheimer's treatment bapineuzumab over safety issues.
More specifically, the companies will halt a segment of the study using the product at its highest dose over concerns that it could be triggering the accumulation of water in the brain in some cases, a condition known as vasogenic edema.
Similar issues were also seen in certain patients enrolled in a Phase II trial of the therapy.
Wyeth and Elan plan to continue other arms of the Phase III trial that are using lower doses of the antibody-based therapy.
Shares of Elan were down 2.89% at $6.39 while Wyeth shares dipped 0.69% to $43.00.
-By Val Brickates Kennedy ; 415-439-6400; AskNewswires@dowjones.com
No comments:
Post a Comment